Compare Nebius Group NV (NBIS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Novavax Inc — how do they compare? Nebius Group NV trades at $221.47 (market cap $59.73B), while Novavax Inc trades at $12.69 (market cap $1.82B). The key difference: Nebius Group NV is far larger — about 32.8× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nebius Group NV for 24 Days and Novavax Inc for 59 Days on average.
| NBIS | NVAX | |
|---|---|---|
Market Cap | $59.73B | $1.82B |
Volume | 21,563,700 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $286.69 | $12.56 |
52-Week Low | $73.87 | $6.22 |
Typical Hold Time | 24 Days | 59 Days |
Enterprise Value | $61.86B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $221.12, down 6.73% over 24 hours amid a bearish technical signal. The stock shows strong analyst support with an 81.82% buy rating and a $288.67 consensus price target, but faces high valuations with a P/E of 845.04 and negative earnings in recent quarters. Recent news highlights AI infrastructure growth potential, including a $37 billion backlog and strategic acquisitions like Inferize, though insider selling and competitive pressures pose concerns.
The outlook for NBIS hinges on executing its AI cloud expansion, with revenue projected to surge from $530 million in 2025 to $1.4 billion in 2026. Risks include elevated debt from aggressive investing, negative net income margins, and potential AI market volatility. The stock offers upside if growth targets are met but remains sensitive to sector sentiment and financing stability.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
